NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded ...

Merck's rebound has already started. The pharmaceutical giant performed well toward the end of 2025. But there could be even ...

Are GLP-1 drugs prescribed for weight loss becoming too outsized a line item for continued coverage through the state ...

My top 10 things to watch Tuesday, Jan. 27 1. The S & P 500 was headed for a slightly higher open this morning ahead of Big Tech earnings tomorrow evening (Meta Platforms and Microsoft ) and Thursday ...

In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s ...

Swedish women’s health specialist Gedea Biotech today announces a planned chief executive (CEO) transition. After close to ...

Investing in Canadian-owned companies reduces those kinds of risks, because it gives us far more control over both the ...

Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intellige | Qilu Pharmaceutical has struck a ...

The Value Fund returned +0.4% in 2025, facing significant currency headwinds and a concentrated market. Read the full 2025 ...

Investing.com -- Citi has initiated coverage of the “Big 6” European pharmaceutical groups with a positive sector view, rating AstraZeneca (LON: AZN ), Novartis AG (SIX: NOVN) and Roche (SIX: ROG) at ...

Good afternoon, ladies and gentlemen, and welcome to Metro Inc. 2026 First Quarter Results Conference Call. [Operator ...

With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously ...